CAJ | 학술논문

可切除结直肠癌肝转移患者术后约有75%的复发率.围手术期的氟尿嘧啶、亚叶酸、奥沙利铂(FOLFOX)化疗较单纯手术可以减少合格入组患者和手术患者的疾病进展风险.但术前化疗可导致肝血管改变和脂性肝炎从而增加手术风险.汇总分析显示与单纯手术相比,术后接受氟尿嘧啶和亚叶酸为基础的辅助化疗,有延长无疾病进展生存期的趋势.贝伐单抗无论术前还是术后使用可能均不会增加手术风险.如何合理地选择化疗时机及最佳持续时间等问题尚待解决.
가절제결직장암간전이환자술후약유75%적복발솔.위수술기적불뇨밀정、아협산、오사리박(FOLFOX)화료교단순수술가이감소합격입조환자화수술환자적질병진전풍험.단술전화료가도치간혈관개변화지성간염종이증가수술풍험.회총분석현시여단순수술상비,술후접수불뇨밀정화아협산위기출적보조화료,유연장무질병진전생존기적추세.패벌단항무론술전환시술후사용가능균불회증가수술풍험.여하합리지선택화료시궤급최가지속시간등문제상대해결.
Relapse may occur in about 75% of patients who experienced the resection of hepatic metas-tases from coloreetal cancer. Perioperative chemotherapy with 5-fluorouraeil, leucovorin and oxaliplatin (FOLFOX) can reduce the risk of disease progression in eligible and reseeted patients compared with surgery a-lone. Pre-operative chemotherapy may cause vascular changes and steatohepatitis, which has the potential to in-crease the risks of surgery. A pooled analysis shows a trend of a longer median progression-free survival dura-tion among pest-operative patients who received adjuvant chemotherapy with 5-fluorouraeil and leueovorin-based regimen. Bevaeizumab in either pre-or pest-operative chemotherapy does not increase surgical complications.How to choose the best time and duration of the ebemotherapy needs to be further studied.